Orexigen announces commercialization and distributorship agreement with Valeant Canada
Orexigen Therapeutics announced that Valeant Canada will commercialize Contrave® (naltrexone HCl / bupropion HCl extended release) in Canada. Valeant will be responsible for obtaining Canadian regulatory approval and for all commercialization activity and expenses. August 30, 2016